Menu Close

FDA warns company for sale of unapproved stem cell therapy

Regenxbio’s RGX-181, being developed as a one-time therapy for late-infantile neuronal ceroid lipofuscinosis type 2 disease, was given orphan drug status by the FDA. New guidance governing investigational-use-only and research-use-only in vitro diagnostic … (본문 전체 11/16/2018 12:11 AM)

Dr. Goy on Need for Payment Model for CAR T-Cell Therapy

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center, discusses the affordability of cancer treatment breakthroughs such as chimeric antigen receptor (CAR) T-cell therapy. Although CAR … (본문 전체 11/17/2018 4:46 AM)